Clinical Trial Update: Evaluation of Nalmefene in Impulse Control Disorders in Parkinson's Disease: A Prospective Open Label Study [Phase 2]

View source ↗

Summary

A Phase 2 open-label study is evaluating nalmefene for impulse control disorders in Parkinson's disease. The status of the trial is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Impulse Control Disorders
• Parkinson Disease

Drugs mentioned

• Nalmefene (nalmefene)

Snippet

Sponsor: University Hospital, Clermont-Ferrand | Conditions: Impulse Control Disorders, Parkinson Disease | Phase 2 | Status: UNKNOWN